Human metapneumovirus prevention within reach: advances in vaccines and monoclonal antibodies
The Lancet Microbe · 2026-04 · 7 (4) · 101303
DOI: 10.1016/j.lanmic.2025.101303 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026-04. Verfasst von Heng Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Schoo…. Hauptthemen laut MEDLINE: Metapneumovirus, Paramyxoviridae Infections, Antibodies, Monoclonal, Viral Vaccines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Major Science and Technology Projects of China, Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
Human metapneumovirus (HMPV) is a major respiratory pathogen that commonly causes mild to moderate upper respiratory tract infections in infants, with only a subset progressing to severe lower respiratory disease globally, particularly in older adults (aged ≥60 years) and individuals with compromised immunity. Efforts to develop an HMPV vaccine or immunoprophylaxis are still ongoing. The rapid advancements in understanding the virus's structure, particularly the surface proteins involved in immune evasion and viral fusion, have paved the way for promising vaccine-based and antibody-based interventions. The range now encompasses multiple vaccine candidates and monoclonal antibodies undergoing clinical trials; in particular, vaccines using different platforms such as virus-like particle-based, live attenuated, epitope-based, mRNA-based, vector-based, and plant-based approaches, in addition to monoclonal antibodies aimed at preventing or reducing disease severity. This Review emphasises innovative strategies for HMPV vaccine design and offers a detailed overview of HMPV vaccine candidates that are currently in clinical development, aimed at preventing a prevalent and severe infectious disease affecting young children (aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, China; Key Laboratory…
- Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, China.
- Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
- Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, China. Electronic addr…
- Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, China; College of Life…
Förderung
- National Natural Science Foundation of China
- National Major Science and Technology Projects of China
- Natural Science Foundation of Chongqing Municipality
- Chongqing Medical University
- Natural Science Foundation Project of Chongqing
Zitieren
APA
Li, H., Zhang, J., Wang, K., Bernardini, S., Zhang, H., & Luo, Y. (2026). Human metapneumovirus prevention within reach: advances in vaccines and monoclonal antibodies. The Lancet Microbe, 7(4), 101303. https://doi.org/10.1016/j.lanmic.2025.101303
Vancouver
Li H, Zhang J, Wang K, Bernardini S, Zhang H, Luo Y. Human metapneumovirus prevention within reach: advances in vaccines and monoclonal antibodies. The Lancet Microbe. 2026;7(4):101303. doi:10.1016/j.lanmic.2025.101303
BibTeX
@article{Li2026,
author = {Li, Heng and Zhang, Jianhong and Wang, Kang and Bernardini, Sergio and Zhang, Hong and Luo, Yang},
title = {Human metapneumovirus prevention within reach: advances in vaccines and monoclonal antibodies},
journal = {The Lancet Microbe},
year = {2026},
volume = {7},
number = {4},
pages = {101303},
doi = {10.1016/j.lanmic.2025.101303}
}
EUVIMED